Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of FCGR2A and FCGR3A Gene Variants on the Response to Rituximab in Patients With Glomerular Diseases.

Pharmacology research & perspectives - 1 Jun 2026

Larrosa-García María, Pamplona Irene Agraz, Tolosa Susana Rojo, Morales Alberto Jiménez, Martínez María Teresa Sanz, Gallo Mónica Martínez, Colobran Roger, Vicente Helena Genestal, Pena Nerea Moreno, Macías Roxana Paola Bury, Ronsano José Bruno Montoro

Abstract excerpt

Rituximab is an anti-CD20 monoclonal antibody used in autoimmune diseases, including glomerular diseases. The FCGR2A (rs1801274) and FCGR3A (rs396991) variants have been suggested to affect rituximab efficacy; this study evaluates their impact on rituximab efficacy in glomerular diseases. A clinical trial was performed including adults with glomerular diseases who required rituximab (NEFRTX; EudraCT:...

Read the complete abstract on PubMed

Topics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Immunologic Factors
Share to Polymorphism, Single Nucleotide
Share to Receptors, IgG
Share to Rituximab
Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 42170767
DOI: 10.1002/prp2.70261
PMCID: PMC13240126

Genes

FCGR2A
FCGR3A

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of FCGR2A and FCGR3A Gene Variants on the Response to Rituximab in Patients With Glomerular Diseases.PMID 42170767Read ↗

FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.Semantic proximity Read ↗

Pharmacokinetic characterization of rituximab in patients with glomerular diseasesSemantic proximity Read ↗

Comprehensive genetic and functional analysis of FcγRs in rituximab therapy for autoimmunity reveals a key role for FcγRIIIa on NK cellsSemantic proximity Read ↗

FCGR2A single nucleotide polymorphism confers susceptibility to childhood-onset idiopathic nephrotic syndrome.Semantic proximity Read ↗

Effect of Fcγ-receptor 3a (FCGR3A) gene polymorphisms on rituximab therapy in Hungarian patients with rheumatoid arthritisSemantic proximity Read ↗

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.Semantic proximity Read ↗

The Diagnostic and Prognostic Potential of the B-Cell Repertoire in Membranous NephropathySemantic proximity Read ↗

FCGR2B gene polymorphism rather than FCGR2A, FCGR3A and FCGR3B is associated with anti-GBM disease in Chinese.Semantic proximity Read ↗

Genetic Variation in Low-To-Medium-Affinity Fcγ Receptors: Functional Consequences, Disease Associations, and Opportunities for Personalized MedicineSemantic proximity Read ↗

IgG receptor polymorphisms: risk factors for diseaseSemantic proximity Read ↗

FCGR2B and FCRLB gene polymorphisms associated with IgA nephropathy.Semantic proximity Read ↗

FCGR3A polymorphism : It is helpful for the management of diffuse large B-cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.